Itonic Holdings Ltd. (NASDAQ:ITOC) Sees Significant Decrease in Short Interest

Itonic Holdings Ltd. (NASDAQ:ITOC) was the target of a significant decrease in short interest in September. As of September 15th, there was short interest totaling 62,815 shares, a decrease of 40.4% from the August 31st total of 105,460 shares. Currently, 0.4% of the company’s stock are short sold. Based on an average trading volume of 117,111 shares, the days-to-cover ratio is currently 0.5 days.

Analysts Set New Price Targets

Separately, Weiss Ratings downgraded shares of Itonic from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, September 24th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Itonic has an average rating of “Sell”.

Itonic Trading Up 2.2%

ITOC opened at $0.27 on Wednesday. Itonic has a twelve month low of $0.22 and a twelve month high of $1.15. The company’s 50-day moving average price is $0.29 and its two-hundred day moving average price is $0.31.

Itonic Company Profile

iTonic Holdings Ltd., a healthcare solutions provider, develops and commercializes treatment software and devices used for brachytherapy. Its proprietary treatment planning system is a radioactive particle implantation, a radiotherapy used in treating cancer patients by placing radioactive sources inside the patient that kill cancer cells and shrink tumors. The company offers FTTPS, a treatment planning system for treating various malignant tumors, which could determine the target volume, prescription dose, and dose limitation to protect organs at risks and produce dose distribution plan for brachytherapy for cancer patients.